Plain-English translation of NCT07456696 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Post Traumatic Stress Disorder research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether , an experimental medication, can safely and effectively reduce symptoms of post-traumatic stress disorder in adults. Researchers will compare two different doses of the medication against a placebo (an inactive treatment) to see which works best. The study includes both an active treatment period and a follow-up period to monitor how well the medication works and any side effects.
Although current treatments help some people with PTSD, many patients still struggle with ongoing symptoms even after trying medications or therapy. This trial exists to see whether this new treatment option might help people whose PTSD hasn't improved enough with existing options.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive one injection or dose per week for 4 weeks, and you'll be randomly assigned to receive either the medication at one of two doses or a placebo. You won't know which group you're in. After the 4-week treatment period ends, you'll continue in an 8-week follow-up period where researchers will check on your progress and watch for any side effects. Overall, your participation will span about 12 weeks.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States